GlassScriptPhysician profile
Steven D Kronick
NPI 1144215344
$15,883.01
in general payments reported to CMS, 2019-2025
20 companies · $3,374 in 2025
The $3,374 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,012 · 2020: $919 · 2021: $1,486 · 2022: $1,794 · 2023: $3,307 · 2024: $2,990 · 2025: $3,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,671.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,120.48 | 2019-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $2,582.98 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,631.51 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,592.61 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,385.20 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,357.87 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $1,165.18 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $725.49 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $483.70 | 2020-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $420.77 | 2019-2024 | Fanapt |
| Lundbeck LLC | $392.96 | 2019-2024 | Rexulti |
| Axsome Therapeutics, INC. | $324.13 | 2022-2025 | Auvelity |
| Indivior INC. | $281.18 | 2022-2024 | Perseris |
| Allergan, INC. | $216.73 | 2019-2020 | |
| Corium, LLC | $81.06 | 2022-2023 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33.39 | 2019 | |
| Bausch Health US, LLC | $28.16 | 2019 | |
| Noven Therapeutics, LLC | $22.32 | 2021 | |
| Vertical Pharmaceuticals, LLC | $21.62 | 2019 | |
| Neuronetics, INC. | $15.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kronick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.